501 |
Achieving Optimal Clinical Results After Carotid Stenting: The PROTECT Study and Beyond... |
William A. Gray |
Jun. 23. 09 |
500 |
The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials |
Roxana Mehran |
Jun. 23. 09 |
499 |
Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences |
Martin Bert Leon |
Jun. 23. 09 |
498 |
Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS |
Gregg W. Stone |
Jun. 23. 09 |
497 |
TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI |
Roxana Mehran |
Jun. 23. 09 |
496 |
FAME: Physiologic Lesion Assessment is Necessary in Multi-Vessel PCI |
Pim A.L. Tonino |
Jun. 23. 09 |
495 |
SYNTAX: Anatomic Complexity Determines PCI Outcomes (Practical Use of the SYNTAX Score) |
Patrick W. Serruys |
Jun. 23. 09 |
494 |
HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use |
Gregg W. Stone |
Jun. 23. 09 |
493 |
Coronary Aneurysms After DES |
Jiro Aoki |
Jun. 05. 09 |
492 |
In-Stent Restenosis |
Roxana Mehran |
Jun. 05. 09 |